Boston Trust Walden Corp Lowers Holdings in Amphastar Pharmaceuticals, Inc. $AMPH

Key Points

• Boston Trust Walden Corp reduced its stake in Amphastar Pharmaceuticals by 3.2%, owning approximately 1,176,453 shares valued at $27 million after selling 39,171 shares in the 2nd quarter.
• Multiple hedge funds increased their holdings in Amphastar Pharmaceuticals, including Millennium Management, which saw a 238.5% boost, acquiring over 611,995 shares in the 1st quarter.
• Analyst ratings for Amphastar vary, with Piper Sandler lowering its price target to $25, while Needham & Company upgraded it to a "buy" with a $36 target, reflecting differing market perspectives.

Boston Trust Walden Corp trimmed its position in Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH - Free Report) by 3.2% in the 2nd quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The firm owned 1,176,453 shares of the company's stock after selling 39,171 shares during the quarter. Boston Trust Walden Corp owned 2.50% of Amphastar Pharmaceuticals worth $27,011,000 at the end of the most recent reporting period.

Several other hedge funds have also made changes to their positions in AMPH. Millennium Management LLC lifted its holdings in shares of Amphastar Pharmaceuticals by 238.5% in the 1st quarter. Millennium Management LLC now owns 868,551 shares of the company's stock worth $25,179,000 after buying an additional 611,995 shares during the period. TD Asset Management Inc raised its position in shares of Amphastar Pharmaceuticals by 20.2% in the 1st quarter. TD Asset Management Inc now owns 2,212,142 shares of the company's stock worth $64,130,000 after acquiring an additional 371,856 shares in the last quarter. Royce & Associates LP raised its position in shares of Amphastar Pharmaceuticals by 2,684.3% in the 1st quarter. Royce & Associates LP now owns 247,858 shares of the company's stock worth $7,185,000 after acquiring an additional 238,956 shares in the last quarter. CX Institutional raised its position in shares of Amphastar Pharmaceuticals by 220.5% in the 2nd quarter. CX Institutional now owns 263,283 shares of the company's stock worth $6,045,000 after acquiring an additional 181,136 shares in the last quarter. Finally, Epoch Investment Partners Inc. raised its position in shares of Amphastar Pharmaceuticals by 14.5% in the 1st quarter. Epoch Investment Partners Inc. now owns 1,261,307 shares of the company's stock worth $36,565,000 after acquiring an additional 160,034 shares in the last quarter. 65.09% of the stock is currently owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

AMPH has been the subject of several recent research reports. Piper Sandler reduced their price target on Amphastar Pharmaceuticals from $30.00 to $25.00 and set a "neutral" rating for the company in a research report on Friday, August 8th. Needham & Company LLC raised Amphastar Pharmaceuticals from a "hold" rating to a "buy" rating and set a $36.00 price target for the company in a research report on Tuesday, August 12th. Bank of America boosted their price target on Amphastar Pharmaceuticals from $28.00 to $32.00 and gave the stock a "neutral" rating in a research report on Tuesday, August 26th. Finally, Weiss Ratings reissued a "hold (c-)" rating on shares of Amphastar Pharmaceuticals in a research report on Wednesday, October 8th. Two analysts have rated the stock with a Buy rating and four have issued a Hold rating to the company's stock. According to data from MarketBeat.com, the stock currently has a consensus rating of "Hold" and an average price target of $31.60.

Amphastar Pharmaceuticals Trading Up 1.5%

Shares of NASDAQ:AMPH opened at $23.86 on Wednesday. The business's 50-day moving average is $27.78 and its 200 day moving average is $25.35. Amphastar Pharmaceuticals, Inc. has a 1 year low of $20.39 and a 1 year high of $53.96. The firm has a market capitalization of $1.11 billion, a P/E ratio of 8.94 and a beta of 0.75. The company has a debt-to-equity ratio of 0.80, a current ratio of 3.29 and a quick ratio of 2.21.

About Amphastar Pharmaceuticals

Amphastar Pharmaceuticals, Inc, a bio-pharmaceutical company, develops, manufactures, markets, and sells generic and proprietary injectable, inhalation, and intranasal products in the United States, China, and France. It offers BAQSIMI, a nasal spray for the treatment of severe hypoglycemia; Primatene Mist, an over-the-counter epinephrine inhalation product for the temporary relief of mild symptoms of intermittent asthma; Enoxaparin, to prevent and treat deep vein thrombosis; REXTOVY and Naloxone for opioid overdose; Glucagon for injection emergency kit; and Cortrosyn, for use as a diagnostic agent in the screening of patients with adrenocortical insufficiency.

Want to see what other hedge funds are holding AMPH? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.